Trump administration authorises 172 million barrel SPR drawdown as 32 IEA nations coordinate record emergency oil release
Read More 4 minute read Pharma Industry News Ascletis doses first obesity patients in U.S. Phase IIa trial of once-monthly GLP-1R depot ASC30 Ascletis (HKEX: 1672) begins dosing in U.S. Phase IIa obesity trial of ASC30, its once-monthly small molecule GLP-1R agonist, with topline data expected Q1 2026. bySoujanya RaviJuly 28, 2025